Objectives: Human pythiosis is a life-threatening disease for which no standard treatment protocols with proven efficacy exist. We present the results of our institutional pythiosis treatment protocol, composed of surgery, antifungal agents, iron chelator (only vascular cases) and immunotherapy. Results: Eighteen patients were evaluated. Disease-free surgical margins were obtained in all surviving patients with vascular pythiosis (P ¼ 0.08). Patients who underwent eye enucleation were significantly older than those who did not (P,0.05). Patients with vascular or ocular pythiosis did not differ significantly in the median time from disease onset to first surgery or in the relationship between the type of P. insidiosum antigen and treatment outcomes. In vitro susceptibility profiles of all isolates demonstrated that no single agent or combination treatment was substantially more effective than the others. The highest MIC was detected for amphotericin B, followed in order by voriconazole, fluconazole, anidulafungin, caspofungin, itraconazole and terbinafine. No synergistic effects of the combination drug treatments were found.
Introduction
Human pythiosis, caused by the oomycetous pathogen Pythium insidiosum, was first reported in Thailand in 1985. 1 Although the microscopic morphology of this pathogen is similar to that of fungi, a phylogenetic analysis based on DNA sequences has shown that it is more closely related to diatoms and algae. 2 Krajaejun et al. 3 classified human pythiosis into four categories based on clinical presentation: cutaneous/subcutaneous, ocular, vascular and disseminated disease. Vascular and ocular pythiosis were formerly treated by aggressive surgery to remove all infected tissue, but this treatment led to exceptionally high morbidity rates. A combination of itraconazole and terbinafine has been used for vascular and ocular pythiosis since 1998, when a report was published on the curative effects of this therapy on periorbital infection in a child for whom surgery could not be performed. 4 The additive effect of itraconazole and terbinafine was demonstrated by testing the in vitro susceptibility of the isolate. In the same year, P. insidiosum antigen (PIA) was used for the first time as immunotherapy to successfully treat a surgically # The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com J Antimicrob Chemother 2015; 70: 1885 -1892 doi:10.1093/jac/dkv008 Advance Access publication 27 January 2015 unresponsive deep tissue infection invading the carotid artery. 5 The efficacy of immunotherapy using PIA was subsequently demonstrated only in patients with vascular pythiosis. 6 Nevertheless, due to the very high morbidity and mortality rates associated with both vascular and ocular pythiosis, all treatment modalities, including surgery, antifungal agents and immunotherapy, have been offered to all patients with pythiosis in our centre.
No standard treatment protocols with proven efficacy for this disease have yet been established. Therefore, this study was conducted to present the results of our institutional treatment protocol, which simultaneously utilizes all modalities (surgery, antifungal agents and immunotherapy), and to compare the clinical features between patients who survived or did not require eye enucleation and those who did not survive or did require enucleation. Additionally, the contribution of in vitro susceptibility testing to the prediction of clinical outcomes was investigated.
Materials and methods

Study design and patients
We conducted a retrospective analysis of patients with proven vascular and ocular pythiosis in King Chulalongkorn Memorial Hospital, Bangkok, Thailand from April 2003 to May 2013. No patients developed cutaneous/subcutaneous or disseminated pythiosis during the observation period. The diagnosis was confirmed when two of the following criteria were met: presence of typical pathological features; successful isolation of P. insidiosum; positive western blotting for Pythium antibody; 7 or positive PCR using internal transcribed spacer and cytochrome oxidase II regions. 8 This study was approved by our centre's institutional review board.
Data collection and statistical analysis
Patient characteristics, including age, sex, part of the country where they lived, underlying disease, haemoglobin typing results and anatomical lesions, were collected. Intervention data, including time from disease onset to first surgery, type of surgery, type and duration of antifungal treatment, type of immunotherapy (PIA) and vaccine schedule, were also collected. The primary outcomes were mortality in patients with vascular pythiosis and eye loss in patients with ocular pythiosis. Fisher's exact test and Wilcoxon's rank-sum test were used for data analysis as appropriate.
Vaccine (immunotherapy) preparation
PIA-1 and PIA-2 were composed of endo-and exo-antigens prepared from P. insidiosum strains CBS574.85 (ATCC 58643) and MTPI04, respectively. The preparation method was modified from the original vaccine (patent numbers US 5 948 413 and US 6 287 573 B1). In brief, 5-day-old P. insidiosum in 2% Sabouraud dextrose broth at 378C was killed with 0.02% merthiolate. The precipitated proteins from the disrupted mycelial masses and supernatants were lyophilized and stored at -808C. The PIA concentration was 2.0 mg/mL. 9,10 PIA was administered subcutaneously as shown in Tables 1 and 2 . All patients were provided with information on PIA and were well aware that PIA was still under investigation. Informed consent was obtained from all patients.
In vitro susceptibility testing
The susceptibility profiles of eight clinical P. insidiosum isolates in the zoospore form were investigated at the time of the patients' initial evaluation according to the standard broth microdilution protocol.
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Testing could be performed on only eight clinical isolates because the others died. Briefly, zoospores were prepared from each of the 48-h-old P. insidiosum strains and counted using a haemocytometer. The final concentration of 2×10 3 zoospores/mL was adjusted using RPMI 1640 broth containing L-glutamine and buffered to pH 7.0. Candida parapsilosis (ATCC 22019) and Aspergillus flavus (ATCC 204304) were used as controls for the MIC experiment. All isolates were assayed against polyenes, azoles and echinocandins, all of which are used empirically to treat pythiosis. Antifungal agents included amphotericin B, terbinafine, fluconazole, voriconazole, itraconazole, anidulafungin and caspofungin, the MICs of which ranged from 0.125 to 64 mg/L. The MICs of individual agents and the combination drugs, terbinafine/voriconazole and terbinafine/ itraconazole, were prepared using the chequerboard technique. 12 The results were interpreted based on the fractional inhibitory concentration index (FICI), which was calculated as follows: FICI¼(MIC of drug A in combination/MIC of drug A alone)+(MIC of drug B in combination/MIC of drug B alone). An FICI of ≤0.5 indicated a synergistic effect, an FICI of .0.5-4.0 indicated an indifferent effect and an FICI of .4.0 indicated an antagonistic effect. A solution of 0.05% benomyl was used as a control.
Results
Patient characteristics and treatment modalities
Eighteen patients were enrolled in this study; nine had vascular pythiosis (Table 1 ) and nine had ocular pythiosis ( Table 2 ). All patients with vascular pythiosis had agriculture-related occupations, and seven of the nine were farmers. None of these patients came from the southern or western regions of Thailand. All patients with vascular pythiosis were male and had thalassaemia major. Additionally, eight of the nine patients had been diagnosed with secondary haemochromatosis. Pathological examination revealed that disease-free surgical margins without evidence of infection were achieved in five of the nine patients with vascular pythiosis. Of the nine patients with ocular pythiosis, four were male and six had ocular trauma. Two of them had a past medical history of hypertension and one of them had well-controlled diabetes mellitus type 2. None of them came from the southern or western regions of Thailand. Oral itraconazole, oral terbinafine and PIA were administered to all patients in both groups, excluding patients who underwent definitive surgery. Mild reactions, including local swelling, redness, pruritus and a small erythematous rash, were observed in four patients with vascular pythiosis (two treated with PIA-1, two treated with PIA-2) and in six patients with ocular pythiosis (two treated with PIA-1, four treated with PIA-2). All reactions were noted only after the first dose of the vaccine. The vaccine schedule is presented in Tables 1 and 2 . The schedule was different in each patient. We tended to perform the vaccinations at 2 week intervals until all infected tissues had been completely removed. Vaccination was subsequently performed 1, 3 and 6 months after the definitive surgery. However, if an infectious disease specialist, vascular surgeon or ophthalmologist determined that the disease was very aggressive (rapidly progressive or unresectable), the vaccine interval was changed to every week as the last resort for treatment.
Comparisons of clinical outcomes
Five of the nine patients with vascular pythiosis survived. The mean age of patients who died and survived was 38.0 and 38.2 years, respectively. There was no significant difference in the median time from disease onset to first surgery (4.5 and 6.0 months for patients who died and survived, respectively; Permpalung et al. Four of the nine patients with ocular pythiosis did not undergo eye enucleation. The patients who underwent enucleation were significantly older than those who did not (57.2 and 27.5 years, respectively; P, 0.05). There was no significant difference in the median time from disease onset to first surgery (36 and 33 days in patients who did and did not undergo enucleation, respectively; P ¼ 0.47). Additionally, no significant difference in the occurrence of enucleation associated with the different types of PIA was found (P ¼0.99). No patients developed disease recurrence.
In vitro susceptibility results
Regardless of the source of the isolate, the highest MICs were found for amphotericin B, followed by echinocandins, and the lowest MICs were found for azoles and terbinafine. The MICS of amphotericin B for all eight isolates ranged from 4 to 8 mg/L. Among azoles, the lowest MIC was found for itraconazole in most of the isolates. No synergistic effects of either combination (terbinafine/ voriconazole and terbinafine/itraconazole) were found according to the FICI, which ranged from 1.0313 to 1.1250 (Table 3) .
Discussion
Human pythiosis is associated with very high mortality and morbidity rates. Krajaejun et al. 3 collected data in Thailand from 1985 to 2003 and reported a mortality rate of 40% in patients with vascular pythiosis and an enucleation rate of 79% in patients with ocular pythiosis. From 2003 to 2013 in our centre, 44% of patients with vascular pythiosis died and 55% with ocular pythiosis underwent enucleation. Definitive surgery with adequate surgical margins may be the best indicator of survival in patients with vascular pythiosis. The combination of oral itraconazole, oral terbinafine, PIA and iron chelation therapy does not seem to have any favourable effects on vascular infection without adequate surgery in our centre. Interestingly, age might be one prognostic factor in patients with ocular pythiosis. We found that patients who did not undergo enucleation were significantly younger than those who underwent enucleation. Additionally, 45% of patients in the present study did not undergo enucleation, which is higher than the rates reported in previous studies (12.5% and 21.0%). 3, 12 This higher rate in our study might have been due to the routine administration of PIA in our centre and the oral and topical antifungal agents used in previous studies.
Although the combination of oral terbinafine and itraconazole used in this study might not have had a significant effect on mortality in patients with vascular pythiosis or patients with ocular pythiosis who underwent enucleation, we cannot conclude that this combination does not provide benefits for patients with pythiosis because the isolates obtained from the clinical specimens were susceptible to these medications. The combined use of oral terbinafine and itraconazole has been in practice in our centre since synergistic reactions were demonstrated by broth Permpalung et al. (2) FLC ( 
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Treatment outcomes in ocular and vascular human pythiosis (46) TRB (12) NA (1) glass ball removal (60) FLC (1) A/C, anterior chamber; AMB, amphotericin B; D, day; F, female; FLC, fluconazole; KTC, ketoconazole; id, intradermal; ITC, itraconazole; M, male; NA, natamycin; PK, penetrating keratoplasty; PSC, posaconazole; sc, subcutaneous; TRB, terbinafine; VRC, voriconazole. 4 The combined activity of terbinafine and itraconazole or voriconazole was synergic against 17% -40% of Brazilian P. insidiosum strains that were obtained from animals with pythiosis. 13, 14 This information differs from the results of our in vitro susceptibility testing of Thai P. insidiosum strains in the present study. We did not demonstrate synergistic interactions of terbinafine plus itraconazole or voriconazole in our isolates. This implies that Thai patients might not require more than one systemic antifungal agent for treatment of pythiosis. We hypothesized that these discrepant results may have been secondary to the different reading techniques employed 15 and different pathogen clades used; P. insidiosum isolates from Thailand are classified in clade B TH and C TH , whereas those from Brazil belong to clade A TH . 16 Differences between in vitro and in vivo results have been observed in many microorganisms and are expected because of the many variables that may affect in vivo results. Moreover, Fonseca et al. 17 reported similar susceptibility results by using P. insidiosum zoospores and hyphae in vitro. One of the major challenges in this area is the lack of a suitable animal model for use in the search for effective antimicrobial agents in clinical cases.
The two types of PIA used in this study did not show significant differences in mortality or enucleation rates between patients with vascular and ocular infections; however, no severe reactions were noted in any patients with pythiosis in our centre. PIA-2 tends to be administered in more severe cases at our centre because it is a more potent immunogen and can induce a stronger antibody response. 7 In contrast to ocular pythiosis, all patients with vascular pythiosis had thalassaemia, and almost all had been diagnosed with secondary haemochromatosis. Abnormal iron metabolism has been thought to be associated with the pathogenesis of pythiosis. 18 The results of a study of iron chelation therapy in rabbits revealed that lesion size did not decrease significantly. 19 Iron chelation therapy was also provided to all patients with vascular pythiosis in the present study, although it did not appear to change the treatment outcomes.
Our study has a few limitations. We reported a case series of a rare disease, leading to a small sample size and the chance of type 2 statistical errors. Additionally, the results should be interpreted cautiously in different geographical areas because of the different pathogen clades and possibly different antimicrobial susceptibilities of clinical isolates between geographical regions.
In the past 10 years numerous antimicrobial agents have been successfully evaluated in in vitro susceptibility testing; however, the lack of a suitable animal model for in vivo evaluation has meant that there has been little success in clinical cases. Despite this, early recognition of the infection combined with a multidisciplinary approach including surgery, antifungal agents and immunotherapy has led to better outcomes.
In conclusion, we strongly believe that surgery with adequate surgical margins is the most important indicator of mortality and morbidity among patients with pythiosis. In clinical practice, however, adequate surgery cannot always be performed. In such cases, adjunctive therapy including oral antifungal agents, PIA and iron chelation should be considered on a case-by-case basis. Further research on the in vitro susceptibility of P. insidiosum to other antimicrobial agents and additional immunological studies on Thai PIA are needed.
